Although epidemiological studies of the relationship between cigarette smoking and colorectal cancer risk have been equivocal, a positive association is consistently found for colorectal adenoma development. We performed an epidemiological study to determine whether p53 protein overexpression, in tumours obtained at the time of resection, is associated with cigarette exposure in colorectal cancer. A total of 163 colorectal cancer cases and 326 healthy controls responded to a standardised questionnaire on colorectal cancer risk factors including detailed information on their history of cigarette smoking. All patients' tumours were analysed immunohistochemically for p53 overexpression using an avidin -biotin immunoperoxidase procedure and polyclonal anti-p53 antibody CM 1. Comparison of colorectal cases with controls revealed an elevated risk for ex-smokers (OR= 1.34, 95% CI 0.85 -2.12) and current smokers (OR= 1.13, 95% CI 0.63-2.02) when compared with non-smokers. No dose-response relationship was found for total pack-years of smoking (trend test: P=0.19). However, a trend for total pack -years of smoking was found when p53-positive cases were compared with p53-negative cases suggesting aetiological, heterogeneity (trend test: P = 0.06). Estimating the individual relative risk of developing a p53-positive tumour relative to controls showed no associations for smoking status or total pack -years of smoking. However, when p53-negative cases were compared with controls, an elevated risk was found for ex-smokers (OR= 1.84, 95% CI 1.00 -3.37) and current smokers (OR= 1.78, 95% CI 0.88-3.61). A significant trend of increasing risk was also found for total packyears of smoking (trend test: P =0.03). Colorectal tumours developing through p53-positive dependent pathways were not associated with smoking exposure. A significant increase in risk was observed for the p53-negative independent pathway with smoking. p53 overexpression appears to be associated with smoking exposure in colorectal cancer. 
Cigarette smoking is known to contribute to the development of many cancers. Results from epidemiological studies investigating its role in colorectal cancer have been inconsistent. Whereas some case -control studies have demonstrated an increased risk (Martinez et al., 1981; Dales et al., 1979; Vobecky et al., 1983; Kabat et al., 1986; Jarebinski et al., 1988 Jarebinski et al., , 1989 Slattery et al., 1990; Kune et al., 1992a) , others find no association (Wynder et al., 1969; Haenszel et al., 1973; Williams and Horm, 1977; Graham et al., 1978; Jain et al., 1980; Tuyns et al., 1982; Ferraroni et al., 1989; Olsen and Kronberg, 1993) , or a reduction in risk (Higginson, 1966; Wynder and Shigematsu, 1967; Stazewski, 1969; Haenszel et al., 1980; Papdimitriou et al., 1984; Tajima and Tominaga, 1985; Peters et al., 1989; Choi and Kahyo, 1991) . In contrast, studies of the relationship between smoking and colorectal adenomas have consistently observed a positive relationship (Olsen and Kronberg, 1993; Zahm et al., 1991; Honjo et al., 1992; Kikendall et al., 1991; Hoff et al., 1987; Monnet et al., 1991; Lee et al., 1993; Sandler et al., 1993; Kune et al., 1992b; Demers et al., 1988; Cope et al., 1991; Martinez et al., 1995; Drexler, 1971) . To explore these divergent findings, data from two recent cohort studies were examined (Giovannucci et al., 1994a and b) . Results from both studies were similar and suggest that smoking may act as an initiator of colorectal carcinogenesis. Previous studies may have yielded equivocal results because they failed to allow for the presumably long induction period between smoking onset and colorectal neoplasia.
Carcinogens present in cigarette smoke cause DNA damage and may produce specific mutations. Alterations of TP53 is the most frequent molecular abnormality found in human cancer and is a susceptible target for many exogenous carcinogens and endogenous mutagens in a variety of tumours (Hollstein et al., 1991a; Harris, 1991; Bennett et al., 1991) . Mutation of TP53 induces loss of tumoursuppressor functions and usually results in the overexpression of mutant p53 protein (Lane, 1990) . Overexpression of p53 protein can be detected by immunohistochemistry and correlates well with TP53 mutation (Cordon-Cardo et al., 1994; Umekita et al., 1994) . Mutations and overexpression of p53 have been associated with a history of cigarette exposure in cancers where p53 alterations are an early occurrence in carcinogenesis such as lung (Suzuki et al., 1992; Miller et al., 1992) , head and neck (Field et al., 1991 (Field et al., , 1994 , oesophageal (Hollstein et al., 1991b) , and bladder cancer (Spruck et al., 1993; Zhang et al., 1994a) .
Colorectal carcinogenesis is a multistep process involving adenoma formation and progression to carcinoma due to mutational activation of oncogenes and inactivation of tumour suppressor genes (Fearon and Vogelstein, 1990) . Alteration of TP53 genes is a late event in the adenomacarcinoma sequence and occurs before the transition of large adenomas to carcinomas (Fearon, 1993) .
Given that colorectal adenomas are regarded as precursors of cancer, the repeatedly observed positive association between smoking and adenomas, but not cancer, is puzzling. To examine aetiologic heterogeneity, odds ratios were calculated for the association between p53 nuclear overexpression and smoking. This odds ratio is the odds of smoking exposure in the p53-positive group divided by the odds of smoking exposure in the p53-negative group. Each ofthese odds ratios represents the ratio ofthe relative risk of smoking for p53-positive tumours to the relative risk of smoking for p53-negative tumours. Aetiological heterogeneity is indicated by departures from the value of 1 (Begg and Zhang, 1994) .
With healthy controls used as the referent group, three additional comparisons were made. First, standard analysis was conducted comparing all colorectal cases with controls. To estimate the risk of developing a colorectal tumour through a p53 (positive) dependent pathway, only colorectal patients with p53 + overexpression were compared with controls. To estimate the risk of developing a colorectal tumour through a p53 (negative) independent pathway, colorectal patients with p53-overexpression were compared with controls. (Table IV) . (Fearon, 1993) . Mutation and overexpression of p53 occurs late in colorectal carcinogenesis, before the transition of an adenoma to a carcinoma (Fearon, 1993) . Carcinogens present in tobacco smoke cause DNA damage and may influence TP53 pathways in many human cancers. Associations between p53 mutation/overexpression and tobacco smoking have been observed in tumour sites where this mutation is an early occurrence in the progression to carcinoma such as lung (Suzuki et al., 1992; Miller et al., 1992) , head and neck (Field et al., 1991 (Field et al., , 1994 , oesophagus (Hollstein et al., 1991b) (Zhang et al., 1994b ). Zhang et al. (1995b recently reported no obvious association between tobacco smoking and p53 nuclear expression in colorectal cancer. However, the study had a relatively small sample size and included only patients with Duke's C stage neoplasms.
To investigate the relationship between p53 overexpression and smoking exposure in colorectal cancer, we analysed tumour specimens for p53 protein and categorised them according to the patient's smoking exposure. Case series analysis suggested aetiological heterogeneity for p53 overexpression and smoking exposure and may indicate the presence of distinct causal mechanisms for p53+ cases and p53-cases. To estimate the individual relative risks of developing a p53+ versus a p53-tumour we used a healthy control group. We observed that tumours developing through a p53 +-dependent pathway were unrelated to smoking exposures. However, those tumours developing through a p53 independent pathway were significantly associated with both smoking status and total pack-years of smoking (trend test: P=0.03). These data may suggest that smoking may initiate tumour mutations early in the adenoma-carcinoma sequence, perhaps in apc or ras genes (Fearon and Vogelstein, 1990) 1979) . Carcinogens in smoke could affect the mucosa of the large bowel through direct ingestion or through the circulatory system. Polycyclic aromatic hydrocarbons (PAHs) and heterocyclic amines are two potent carcinogens found in cigarette smoke and are also observed in well-done meat, another risk factor for colorectal cancer (Laden et al., 1995) .
The possibility exists that cigarette smokers consume a diet consisting of fewer protective and more numerous carcinogenic agents. Smokers generally have lower intakes of fruits and vegetables and higher intakes of fats than non-smokers (Subar and Harlan, 1993) . Therefore, the association between p53 (negative) independent tumours and smoking may be confounded by dietary factors associated with this pathway. However in our analysis, a statistically significant doseresponse relationship for the association between p53 negative patients and total pack-years of smoking existed (trend test: P = 0.03), even after adjustment for alcohol, meat, cruciferous vegetables and body mass index. Therefore, it is unlikely that confounding by diet completely accounts for the association between cigarette smoking and the p53 independent pathway.
The use of hospital/screening clinic controls in a casecontrol comparison may lead to bias since controls may overrepresent healthier lifestyles. However, the odds ratios observed in our case-control comparison are similar to those reported in three recent population-based cohort studies (Giovannucci et al., 1994a and b; Heineman et al., 1995) . Additionally, the primary use of this control group is to assist in the estimation of the individual relative risks for p53 positive and p53 negative tumour development separately, for smoking exposure variables. This bias is of less concern in our case series analysis since patients are unaware of their p53 status.
The positive consistent finding that smoking increases the risk of colorectal adenoma formation but not cancer has been problematic. Our results suggest that results of studies of colorectal cancer risk and smoking may be affected by inclusion of patients whose tumours harbour p53 genetic alterations that occur late in the adenoma -carcinoma sequence, that are unrelated to smoking history. In addition, smoking was significantly associated in tumours developing through a p53 independent pathway, perhaps the result of initiation of mutations in genes early in the carcinogenic process that do not need a p53 alteration to progress from an adenoma to a carcinoma.
